Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story

Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but decline sequentially, with adjusted EPS expected to fall 64.3% due to elevated R&D and SG&A expenses. LUMRYZ's patient growth and LYBALVI's prescription trends are key near-term metrics, while Alixorexton's clinical progress bolsters long-term investment appeal.

Seeking Alpha • 2 hours ago

Alkermes to Report Third Quarter Financial Results on November 3, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webca.

Business Wire • Oct 20, 2026

Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 20, 2026

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society's (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes' sleep portfolio following the acquisition.

Business Wire • Oct 13, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

Zacks Investment Research • Oct 9, 2026

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Seeking Alpha • Oct 7, 2026

LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?

LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.

Zacks Investment Research • Sep 30, 2026

Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver

Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental revenue, leveraging existing commercial infrastructure and delivering operating leverage with a limited SG&A increase. ALKS faces a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales post-March 2028, but the opportunity remains financially meaningful.

Seeking Alpha • Sep 26, 2026

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

Zacks Investment Research • Sep 22, 2026

How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

Investors Business Daily • Sep 21, 2026